Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Total Current Liabilities (2020 - 2025)

Cytek Biosciences' Total Current Liabilities history spans 6 years, with the latest figure at $77.8 million for Q4 2025.

  • For Q4 2025, Total Current Liabilities rose 14.99% year-over-year to $77.8 million; the TTM value through Dec 2025 reached $77.8 million, up 14.99%, while the annual FY2025 figure was $77.8 million, 14.99% up from the prior year.
  • Total Current Liabilities reached $77.8 million in Q4 2025 per CTKB's latest filing, up from $75.2 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $77.8 million in Q4 2025 to a low of $28.2 million in Q2 2021.
  • Average Total Current Liabilities over 5 years is $53.9 million, with a median of $55.6 million recorded in 2024.
  • Peak YoY movement for Total Current Liabilities: skyrocketed 50.36% in 2022, then dropped 2.26% in 2024.
  • A 5-year view of Total Current Liabilities shows it stood at $33.2 million in 2021, then surged by 47.8% to $49.0 million in 2022, then increased by 14.65% to $56.2 million in 2023, then increased by 20.34% to $67.7 million in 2024, then increased by 14.99% to $77.8 million in 2025.
  • Per Business Quant, the three most recent readings for CTKB's Total Current Liabilities are $77.8 million (Q4 2025), $75.2 million (Q3 2025), and $73.3 million (Q2 2025).